Background: Insect-bite hypersensitivity (IBH) in horses is a chronic allergic dermati-
| INTRODUCTION
Insect-bite hypersensitivity (IBH) in horses is caused by an allergy against insect bites, more specifically against Culicoides spp. It is a severe and chronic disease affecting a large number of horses worldwide. Although IBH is the best characterized allergic dermatitis in horses, effective treatment is still lacking. [1] [2] [3] [4] [5] [6] [7] [8] We recently proposed a new therapeutic vaccination targeting eosinophils by active vaccination against IL-5. 9 Host-made auto-antibodies induced by active vaccination show overall similar advantages and safety profiles as monoclonal antibodies (mAb) administered via passive vaccination. A major drawback of mAbs is the potential induction of anti-mAb antibodies and their relative short half-life, thus limiting its clinical long-term use. On the other hand, a specific concern of therapeutic vaccines is the potential irreversibility of the antibody responses, potentially causing lifelong blockage of target self-molecules. 10 The most prominent therapeutic vaccine in veterinary use is the anti-boar vaccine Improvac targeting cytokines in inflammatory conditions and personalized anticancer vaccines. 13, 14 Originally described as an IgE-dependent type-I allergy, it has recently emerged that IBH also shows characteristics of a delayedtype hypersensitivity (DTH) allergic response. Eosinophils may be a common denominator, as they can play a key role in both allergic reactions. Indeed, allergic lesions are characterized by strong eosinophilic inflammation 9, 15 and it has previously been suggested that eosinophils strongly contribute to IBH disease pathology. 16 This notion is supported by the fact that increased expression of IL-4, IL-5, and IL-13 mRNA is found in acute lesions. IL-5 is the key cytokine for the development, survival, and activation of eosinophils. In addition, established lesions show enhanced levels of mRNA encoding the chemokines CCL11 (Eotaxin-1) and CCL2 (monocyte chemotactic protein 1 (MCP1)). 17 Eotaxin-1 is a potent eosinophil chemoattractant and binds to the CCR3 receptor. Furthermore, Eotaxin-1 is involved in eosinopoiesis and cooperates with IL-5 at inducing blood eosinophilia. 18, 19 Together with IL-5, Eotaxin-1 stimulates eosinophils to migrate from blood to tissue 19 and locally produce a large number of pro-inflammatory and toxic mediators. 17, 20 We recently found that eosinophils are not only upregulated locally within lesions but also systemically in blood and that these blood eosinophil levels strongly correlate with disease severity. 9 Hence, blood eosinophilia might be a new and easy-to-measure diagnostic disease activity marker of IBH and related diseases.
In order to target eosinophils, we developed a therapeutic vaccine targeting equine IL-5 (eIL-5). IL-5 is a classical Th2 cytokine and, as discussed above, is the master regulator for eosinophil-mediated inflammation. 18, 21, 22 Hence, IL-5 is known to be an eosinophil lineage-specific cytokine, thereby having limited effects on other lineages. 23 In contrast to the veterinary field, IL-5 blocking agents are already well known for use in human hyper-eosinophilic conditions such as eosinophilic asthma. Three monoclonal antibodies, two blocking IL-5 directly (Reslizumab and Mepolizumab), and one blocking the IL-5Rα (Benralizumab) received market authorization over the past two years. All IL-5 pathway interfering antibodies and in particular both anti-IL-5 antibodies have a very good safety profile collected over the past 10 years of clinical testing and use. 24 In order to induce IL-5-specific neutralizing antibodies, we have developed a virus-like particle (VLP)-based IL-5 vaccine, which can overcome B cell unresponsiveness. 9, 25 Our previously published study shows that vaccination of horses resulted in high levels of
G R A P H I C A L A B S T R A C T
Basic vaccination regimen consisting of three vaccine injections in the first treatment year induces sufficient antibody titers leading to significant improvement of insect bite hypersensitivity (IBH) lesion scores. A single booster vaccine injection in the second treatment year re-induces anti-IL-5 antibody titers leading to enhanced improvement of IBH lesion scores. Anti-IL-5 vaccination in horses significantly reduces eosinophil levels in blood.
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| 573 IL-5-specific antibodies and statistically significant reductions of lesion scores in vaccinated IBH-affected horses when compared to placebo-treated IBH-affected horses. 9 Here, we document a followup study subsequent to the placebo-controlled double-blind study of the 1st year. The current study was performed in the 2nd year with a semi-crossover design. Three main questions were addressed. Group 2 horses. 9 Vaccine was administered subcutaneously without the presence of adjuvants. In the observational year ("Pre-season"), the eczema lesions of all horses had been recorded monthly (after study recruitment) and blood eosinophil levels and a serum IgE against insects had been determined at a single time point. In both treatment years ("1st year" and "2nd year") before vaccination and at the end of each study year, health status in blood and parasite levels in stool of all horses were determined. During the treatment years, all horses were bled monthly in order to monitor antibody titers and eosinophil levels. Additionally, eczema lesions were scored at least monthly.
| IBH lesion scoring
Described in Ref. 9.
| Blood withdrawal
Blood was collected from V. jugularis at the intersection of the proximal to median third of the neck. (February) and a booster in week 19 (June; n = 13).
| Linear epitope mapping
Linear epitope mapping using serum of three different eIL-5-VLP vaccinated horses was performed by PEPperPRINT GmbH, Heidelberg, Germany. Negative control was naive serum prior to vaccination.
| Model structure equine IL-5 dimer
The monomeric equine IL-5 was plotted onto the dimeric human IL-5 crystal structure using Pymol. The monomeric eIL-5 structure was calculated by Kallber et al. 
| Statistics
All graphs comparing vaccinated horses vs placebo horses show mean and standard error of mean (SEM). Statistical analysis was performed by paired, one-tailed non-parametric Wilcoxon test. Considered to be statistically significant were P-values lower than 0.05: *P < 0.05; **P < 0.01; ***P < 0.001. 
| Antibody titer responses upon vaccination
Antibody titers in serum of horses were evaluated once per month. The booster injection efficiently increased the antibody titer in midseason ( Figure 1A and B). Anti-CuMV TT titers followed the same pattern; however, peak levels were lower when compared to anti-IL-5 levels, indicating that the immune response was dominated by anti-IL-5 ( Figure 1C and D) . Figure 3D . In parallel, the dimeric huIL-5 was mapped onto the huIL-5Rα (Figure 3E) . Furthermore, the huIL-5 epitope, which is recognized by the Figure 3D and E: magenta-major equine epitope, yellow-reslizumab epitope). October in "Pre-evaluation" year (n = 34), "1st year" (placebo-controlled double-blind randomized study, n = 34), and "2nd year" (half crossover follow-up vaccination, n = 30). Months with more than one measurement show mean values. A, Group 1 horses in "Pre-season" (dotted gray line, n = 15), blinded placebo treatment "1st year" (continuous gray line, n = 15), and first season with vaccine treatment "2nd year" (dotted black line, n = 13). B, Group 2 horses in "Pre-season" (dotted gray line, n = 19), blinded vaccine treatment "1st year" (dotted black line, n = 19), and follow-up second year vaccine treatment (continuous black line, n = 17). C, Area under the curve of mean average lesion score per year of Group 1 (empty circles) and Group 2 (filled circles). D, Average (of monthly mean) lesion score per year of single horses in Group 2 (black lines) and Group 1 (gray lines) during "Pre-season" (pre), placebo treatment or eIL-5-CuMV TT vaccination "1st year," and eIL-5-CuMV TT vaccination "2nd year". E, Mean average lesion score of all Group 1 horses during "Pre-season" year (pre, gray pattern, n = 15), blinded placebo treatment "1st year" (filled gray, n = 15), and eIL-5-CuMV TT vaccination "2nd year" (filled black, n = 13). F, Mean average lesion score of all Group 2 horses during "Pre-season" (pre, gray pattern, n = 19), blinded first year eIL-5-CuMV TT vaccination "1st year" (filled black, n = 19), and followup eIL-5-CuMV TT vaccination "2nd year" (black pattern, n = 17). All graphs include all horses, n = 34 ("Pre-season", "1st year"), n = 30 ("2nd year"), independent of antibody titer: ITT, intention to treat; IBH, insect-bite hypersensitivity helminth presence of post-and pre-vaccination is comparable between Group 1 and Group 2 in "1st year" and "2nd year," with a tendency toward lower helminthes in 2nd year vaccinated horses of Group 2 ( Figure S4B ). In general, however, helminth presence in autumn was higher than in spring in both groups probably due to higher exposure on the pasture during the summer months. Of note, the only helminth parasite type found in any of the horses was the strongyle nematode, which is the most common one for horses. No other parasites (nematode and cestode) were detected. With regards to other side effects, we did not observe health issues possibly related to the vaccine. In particular, no indication for immune complex disease was found, neither on the skin nor by blood chemistry kidney parameters (blood urea, serum creatinine, albumin, total protein, sodium, potassium, sodium/potassium ratio, calcium, phosphate) before and after each IBH season (data not shown).
| Blood eosinophilia

| DISCUSSION
In the present study, we demonstrate that targeting eosinophils by vaccinating against IL-5 may be a long-term therapy for IBH in horses. We have previously shown a therapeutic effect of this VLPbased vaccine in a one-year placebo-controlled clinical study. 9 Here, we report that vaccination can be successfully performed over a sec- In the normal physiological state, enhanced numbers of eosinophils are only found in blood when increased numbers of eosinophils are required in tissues. The eosinophil has three life phases, the bone marrow, blood, and final tissue phase. The blood-to-tissue ratio in humans is about 1:100. 32 The blood phase is considered merely to Depending on the vaccination regimen and vaccine formulation in "1 st year" therapy, between 50% and 70% of horses reached an ISI 50, a 50% and higher improvement of symptoms. "2nd year" therapy was able to further increase the 50% response to almost 90%. A 75% and higher improvement of symptoms was achieved in 20% to 30% in "1st
year" therapy, and almost in 50% of horses in "2nd year" therapy.
Thus, we confirmed a clinical effect during the first year vaccination (basic vaccination) and a continuous and even stronger clinical benefit in the follow-up year, which can be explained by more stable and longlasting antibody titers and perhaps increased affinity.
Vaccination with eIL-5-CuMV TT was safe and well tolerated. 
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